https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
LRuas2022-12-01 15:49:362022-12-01 16:06:09LSX and Jefferies – Insights from the busiest week in European biotech 
LSX and Jefferies – Insights from the busiest week in European biotech
The LSX Inv€$tival Showcase kicked off a hectic week in life…
Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022
For those that were unable to attend on Optimum’s 14th Annual…
Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage
Dan Mahony and Gareth Powell are long time, successful life sciences…
Sector Moves: November 2022
November moves 2022
Analysts and Banking
Kegan McColgan-Bannon…
Analysts and Banking
Kegan McColgan-Bannon…
Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight
Financing growth: Walking the tightrope
InsightIn the context…
InsightIn the context…
Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference
We were proud to host a fantastic panel chaired by BioCentury’s…
Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec
We were privileged to hear visionary insights during Mike Ward’s…
An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor…
A Q&A by Verona Pharma ahead of World Lung Cancer Day
This World Lung Day, Verona Pharma is raising awareness of the…
Optimum’s 14th Annual Healthcare Investor Conference
6TH OCTOBER 2022 | LONDON
STORM Therapeutics: 2022 Winner of “Fierce 15”
The award highlights significant company growth and advancement in the field of RNA modifying enzymes (RME) as STORM aims to become the global leader in the field of RME.
Use of Inbiomotion’s MAFTEST® leads to huge reduction in breast cancer mortality
Inbiomotion, a Barcelona based company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage breast cancer patients, recently presented analyses of Phase 3 data from landmark trials.
Insights
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
The burden of COPD and potential impact of novel therapeutics by Verona Pharma
/in InsightsA Q&A with Rising Leader Thijs Cohen Tervaert of INKEF
/in InsightsHealthTech For Care’s HealthTech Innovation Days
/in InsightsISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
/in InsightsA Q&A with Rising Leader Dr. Mårten Steen of HealthCap
/in InsightsThe Future of Bio Innovation
/in Insights